Early detection plays a crucial role in cancer treatment. In many cases, cancer is diagnosed only after symptoms appear or the disease has progressed to an advanced stage. Detecting cancer at an earlier stage can improve treatment options and the chances of successful outcomes. In an important development in medical research, Bengaluru-based Strand Life Sciences has developed CancerSpot, a blood-based test designed to detect signals associated with multiple types of cancer using a single blood sample.
Introduction
The test combines advanced DNA sequencing with Artificial Intelligence (AI) to identify cancer-related changes in DNA, particularly patterns of DNA methylation. A recent Indian study involving 1,480 participants across 43 hospitals has provided new insights into how circulating DNA in the bloodstream can help improve cancer detection.
The research has also challenged an earlier scientific assumption that DNA released by immune cells could dilute tumour-related DNA signals and make cancer detection more difficult. These findings could contribute to the development of more effective multi-cancer early detection technologies.
What is CancerSpot?
NABARD 2021-2024 Cutoff Analysis | What we can Learn? #nabard_grade_a_exam #nabard_cutoffTap to play · from the C4S channel
- CancerSpot is a blood-based multi-cancer early detection (MCED) test developed by Strand Life Sciences, a Bengaluru-based genomics and diagnostics company.
- It uses DNA sequencing and AI-based analysis to identify patterns associated with cancer in blood samples.
- Unlike conventional diagnostic approaches that often investigate one suspected cancer at a time, multi-cancer detection tests aim to identify signals associated with several types of cancer through a single blood test.
Key Features of CancerSpot
- Developed by: Strand Life Sciences.
- Location: Bengaluru, Karnataka.
- Technology: DNA sequencing and Artificial Intelligence.
- Testing approach: Blood-based cancer detection.
- Molecular marker: DNA methylation patterns.
- Coverage: Designed to detect signals associated with multiple cancer types.
- Research coverage: 14 types of cancer.
- Main objective: Improve the possibility of detecting cancer through a minimally invasive blood test.
The technology aims to identify cancer-associated signals without requiring a tissue biopsy for the initial blood-based screening. However, a positive result may still require imaging, biopsy and other clinical investigations to confirm the diagnosis.
A clean PDF of this page with the C4S header — it opens right away, and the link comes to your WhatsApp too.
How Does CancerSpot Work?
To understand how CancerSpot works, it is important to understand how DNA fragments enter the bloodstream.
Step 1: Release of DNA into the bloodstream
- Cells in the human body naturally die and release small fragments of DNA into the bloodstream.
- These fragments are known as cell-free DNA (cfDNA).
- They circulate in the blood and can originate from different types of cells, including normal body cells and immune cells.
- In people with cancer, some of these DNA fragments also originate from tumour cells.
- These tumour-derived fragments may contain molecular patterns that help researchers identify the presence of cancer.
Step 2: Collection of a blood sample
- A blood sample is collected from the individual.
- The laboratory separates and analyses the cell-free DNA present in the blood.
- The objective is to identify small amounts of tumour-associated DNA among a much larger quantity of DNA released by normal cells.
Step 3: DNA sequencing
- The test uses advanced DNA sequencing technology to examine the genetic material present in the sample.
- Sequencing helps researchers analyse DNA fragments and identify molecular patterns that may be associated with cancer.
Step 4: Analysis of DNA methylation
- One of the important features of CancerSpot is its focus on DNA methylation.
- DNA methylation refers to a chemical modification in which methyl groups are attached to DNA, particularly at specific cytosine bases.
- These modifications influence how genes function and whether certain genes are switched on or off.
- Cancer cells often show abnormal methylation patterns compared with normal cells.
- By identifying these differences, the test attempts to recognise cancer-associated DNA signals.
Step 5: Artificial Intelligence-based analysis
- CancerSpot combines DNA sequencing with computational and AI-based analysis.
- AI-based models examine complex methylation patterns and help distinguish cancer-associated signals from normal DNA patterns.
- The final analysis is used to identify whether the blood sample contains signals associated with cancer.
In simple words: CancerSpot examines DNA fragments circulating in the blood, identifies unusual chemical patterns and uses AI-based analysis to detect signals that may indicate the presence of cancer.
What is DNA Methylation and Why Is It Important?
DNA methylation is an important biological process that regulates gene activity without changing the actual DNA sequence. In this process, small chemical groups called methyl groups are attached to specific regions of DNA. These chemical modifications influence how genes are expressed and help regulate several biological activities.
DNA Methylation in Normal Cells
- It helps regulate gene expression.
- It plays a role in normal cellular development.
- It helps maintain normal cellular functions.
DNA Methylation in Cancer Cells
Cancer cells may develop abnormal DNA methylation patterns. These changes can affect genes responsible for controlling cell growth, cell division and other important cellular processes. Such abnormal patterns can act as molecular signals that help researchers distinguish cancer-associated DNA from DNA released by normal cells. This is why DNA methylation has become an important area of research in cancer detection.
4. What is Cell-Free DNA (cfDNA)?
Cell-free DNA refers to small DNA fragments that circulate freely in body fluids, particularly blood plasma. These fragments are released when cells die or undergo other cellular processes. In healthy individuals, most circulating DNA comes from normal body cells. In cancer patients, some of the circulating DNA may originate from tumour cells. This is known as circulating tumour DNA (ctDNA).
Difference Between cfDNA and ctDNA
| Basis | cfDNA | ctDNA |
|---|---|---|
| Full form | Cell-free DNA | Circulating tumour DNA |
| Origin | Different cells of the body | Tumour cells |
| Presence | Healthy and cancer patients | Generally associated with cancer |
| Nature | Broad category of DNA fragments | A fraction of cfDNA |
| Importance | Provides information about cellular activity | Helps identify cancer-associated molecular changes |
Important: ctDNA is a component of cfDNA, not a completely separate category of circulating DNA.
Recent Study on CancerSpot: Important Findings
A significant study associated with CancerSpot has been published in the prestigious scientific journal Proceedings of the National Academy of Sciences (PNAS). The research was conducted over approximately four years as part of the development and clinical validation of the technology.
Key Details of the Study
| Particulars | Findings |
|---|---|
| Test | CancerSpot |
| Developed by | Strand Life Sciences |
| Study participants | 1,480 |
| Hospitals involved | 43 hospitals across India |
| Cancer types studied | 14 |
| Research focus | Circulating cell-free DNA and cancer-associated methylation |
| Journal | Proceedings of the National Academy of Sciences (PNAS) |
| Study objective | Understand factors influencing cancer detection through blood-based DNA analysis |
Major Finding: Higher Circulating DNA Strengthens Cancer Signals
One of the most interesting findings was that higher levels of circulating cell-free DNA were associated with stronger cancer-related signals and better detection sensitivity. This finding challenged an earlier scientific assumption.
Researchers had expected that increased DNA released by immune cells in cancer patients would dilute the relatively small amount of tumour-derived DNA in the bloodstream. In theory, this dilution could make it more difficult to detect cancer. However, the study observed the opposite. It found that higher levels of circulating DNA were associated with stronger cancer-associated methylation signals. This suggests that DNA released by tumour cells and immune cells may increase together in cancer patients.
As a result, the presence of more circulating DNA did not necessarily weaken the cancer-related signal. The findings provide new insights into the relationship between tumour activity, immune-system responses and blood-based cancer detection.
What Were the Detection Results?
The study reported promising results for CancerSpot in an independent validation cohort.
- Overall cancer detection sensitivity: 72%.
- False-positive rate: 1.4%.
Understanding these two terms is important.
- Sensitivity: Sensitivity measures how effectively a test identifies people who actually have the disease.
- A sensitivity of 72% means that the test detected approximately 72 out of every 100 cancer cases in the particular validation setting.
- False-positive rate: This refers to the proportion of people without cancer who incorrectly receive a positive result.
- A false-positive rate of 1.4% is encouraging, although it does not eliminate the possibility of unnecessary follow-up investigations.
- These figures are study-specific results and should not be interpreted as guaranteed performance for every cancer type or for general-population screening.
Which Types of Cancer Can CancerSpot Detect?
CancerSpot has been studied as a multi-cancer detection technology covering 14 cancer types. The research and company announcements describe its potential application across several solid cancers.
These include:
- Lung cancer
- Liver cancer
- Stomach cancer
- Kidney cancer
- Ovarian cancer
- Oesophageal cancer
- Urinary bladder cancer
- Uterine cancer
- Breast cancer
- Prostate cancer
The research covers 14 cancer types in total. The list above includes examples of cancers discussed in company announcements, rather than an exhaustive list of all 14. The broader objective is to identify molecular signals associated with different cancers through one blood sample.
CancerSpot vs Traditional Cancer Detection Methods
Traditional cancer diagnosis involves different methods depending on the suspected cancer, its location and the patient’s symptoms. These methods include imaging, endoscopy, laboratory investigations and tissue biopsy. CancerSpot introduces a different approach by examining cancer-associated DNA patterns in the bloodstream.
| Basis | Traditional diagnostic methods | CancerSpot |
|---|---|---|
| Approach | Depends on suspected cancer | Blood-based molecular analysis |
| Sample | May require tissue or other samples | Blood sample |
| Technology | Imaging, pathology and laboratory tests | DNA sequencing and AI |
| Detection | Often investigates a specific suspected cancer | Designed for multiple cancer types |
| Invasiveness | Some procedures are invasive | Blood collection is minimally invasive |
| Confirmation | Depends on diagnostic method | Positive signals require clinical confirmation |
CancerSpot is not a replacement for established diagnostic procedures. It is a developing approach that may complement existing cancer detection strategies.
Why Is CancerSpot Important for India?
Cancer continues to be a major public health challenge in India. Delayed diagnosis, limited awareness, inadequate access to specialised healthcare and the high cost of certain investigations can create difficulties in cancer management. CancerSpot may contribute to addressing some of these challenges.
1. Potential for earlier detection
A blood-based test designed to identify multiple cancer-associated signals may help identify individuals who need further medical evaluation.
2. Minimally invasive testing
Blood collection is simpler than many invasive diagnostic procedures.
3. Multiple cancer detection
The technology aims to identify signals associated with different cancers through a single test.
4. Contribution to precision medicine
The use of DNA sequencing and AI represents an important development in genomic medicine and personalised healthcare.
5. Strengthening India's biotechnology sector
The development of advanced genomic diagnostic technologies by Indian companies highlights India’s growing contribution to medical research and biotechnology.
Limitations of CancerSpot
Despite its potential, CancerSpot should not be considered a perfect cancer detection tool. Some important limitations need to be understood.
- A negative result does not completely rule out cancer.
- A positive result does not automatically confirm cancer.
- Further clinical investigations may be required.
- Detection performance can differ across cancer types and disease stages.
- Large-scale independent validation is important before establishing its role in population-wide screening.
- Its effectiveness in reducing cancer-related deaths has not yet been established by the reported study.
The test should not replace established screening programmes such as recommended breast, cervical and colorectal cancer screening. Individuals should consult qualified healthcare professionals before making decisions about cancer screening or diagnosis.
Important Organisations and Institutions
| Organisation | Role |
|---|---|
| Strand Life Sciences | Developer of CancerSpot |
| Reliance Industries | Parent group associated with Strand Life Sciences |
| PNAS | Scientific journal publishing the research |
| Hospitals across India | Participated in the multi-centre research |
Conclusion
CancerSpot represents an important development in India’s growing field of genomic medicine and cancer diagnostics. By combining DNA sequencing, methylation analysis and Artificial Intelligence, the technology aims to identify signals associated with multiple cancers through a single blood sample.
The recent study involving 1,480 participants across 43 hospitals has also provided an interesting insight into the relationship between circulating DNA, tumour activity and immune-system responses. Although the findings are promising, further independent validation and clinical research will be essential to establish the role of CancerSpot in routine cancer screening. The development highlights how biotechnology, genomics and Artificial Intelligence are increasingly working together to improve disease detection and strengthen modern healthcare.
Frequently Asked Questions (FAQs)
Q1. What is CancerSpot?
CancerSpot is a blood-based multi-cancer early detection test developed by Bengaluru-based Strand Life Sciences. It uses DNA sequencing and AI-based analysis to identify cancer-associated DNA methylation patterns.
Q2. Who developed CancerSpot?
It was developed by Strand Life Sciences, a Bengaluru-based genomics and diagnostics company.
Q3. What technology does CancerSpot use?
It combines DNA sequencing, DNA methylation analysis and Artificial Intelligence.
Q4. What is DNA methylation?
DNA methylation is a chemical modification of DNA that influences gene expression without changing the underlying DNA sequence.
Q5. What is cfDNA?
Cell-free DNA refers to small DNA fragments that circulate freely in the bloodstream.
Q6. What is ctDNA?
Circulating tumour DNA refers to DNA fragments released by tumour cells into the bloodstream.
Q7. What was the major finding of the recent CancerSpot study?
The study found that higher levels of circulating cell-free DNA were associated with stronger cancer-related methylation signals and improved cancer detection sensitivity.
Q8. How many hospitals participated in the study?
A total of 43 hospitals across India participated in the research.
Q9. What was the reported detection sensitivity of CancerSpot?
The test demonstrated 72% sensitivity in an independent validation cohort.
Q10. Does CancerSpot replace a cancer biopsy?
No. It may help identify cancer-associated signals through a blood sample, but further investigations, including imaging and tissue biopsy where appropriate, may be necessary to confirm cancer.





